» Articles » PMID: 10412038

Inhibition of Osf2/Cbfa1 Expression and Terminal Osteoblast Differentiation by PPARgamma2

Overview
Journal J Cell Biochem
Date 1999 Jul 21
PMID 10412038
Citations 183
Authors
Affiliations
Soon will be listed here.
Abstract

Cells of the bone marrow stroma can reversibly convert among different phenotypes. Based on this and on evidence for a reciprocal relationship between osteoblastogenesis and adipogenesis, we have isolated several murine bone marrow-derived clonal cell lines with phenotypic characteristics of osteoblasts or adipocytes, or both. Consistent with a state of plasticity, cell lines with a mixed phenotype synthesized osteoblast markers like type I collagen, alkaline phosphatase, osteocalcin, as well as the adipocyte marker lipoprotein lipase, under basal conditions. In the presence of ascorbic acid and beta-glycerophosphate-agents that promote osteoblast differentiation-they formed a mineralized matrix. In the presence of isobutylmethylxanthine, hydrocortisone, and indomethacin-agents that promote adipocyte differentiation-they accumulated fat droplets, but failed to express adipsin and aP2, markers of terminally differentiated adipocytes. Furthermore, they were converted back to matrix mineralizing cells when the adipogenic stimuli were replaced with the osteoblastogenic ones. A prototypic cell line with mixed phenotype (UAMS-33) expressed Osf2/Cbfa1-a transcription factor required for osteoblast differentiation, but not PPARgamma2-a transcription factor required for terminal adipocyte differentiation. Stable transfection with a PPARgamma2 expression construct and activation with the thiazolidinedione BRL49653 stimulated aP2 and adipsin synthesis and fat accumulation, and simultaneously suppressed Osf2/Cbfa1, alpha1(I) procollagen, and osteocalcin synthesis. Moreover, it rendered the cells incapable of forming a mineralized matrix. These results strongly suggest that PPARgamma2 negatively regulates stromal cell plasticity by suppressing Osf2/Cbfa1 and osteoblast-like biosynthetic activity, while promoting terminal differentiation to adipocytes.

Citing Articles

Pharmacologic or genetic interference with atrogene signaling protects against glucocorticoid-induced musculoskeletal and cardiac disease.

Sato A, Cregor M, McAndrews K, Schurman C, Schaible E, Shutter J JCI Insight. 2024; 9(21).

PMID: 39405125 PMC: 11601705. DOI: 10.1172/jci.insight.182664.


Function and Regulation of Bone Marrow Adipose Tissue in Health and Disease: State of the Field and Clinical Considerations.

Zhang X, Tian L, Majumdar A, Scheller E Compr Physiol. 2024; 14(3):5521-5579.

PMID: 39109972 PMC: 11725182. DOI: 10.1002/cphy.c230016.


Effects of Denosumab and Bisphosphonates on Glucocorticoid-induced Osteoporosis in Patients with Neuroimmunological Disorders.

Handa H, Uzawa A, Mori M, Yasuda M, Onishi Y, Akamine H Intern Med. 2024; 64(4):543-549.

PMID: 38987183 PMC: 11904454. DOI: 10.2169/internalmedicine.3954-24.


Cell signaling and transcriptional regulation of osteoblast lineage commitment, differentiation, bone formation, and homeostasis.

Zhu S, Chen W, Masson A, Li Y Cell Discov. 2024; 10(1):71.

PMID: 38956429 PMC: 11219878. DOI: 10.1038/s41421-024-00689-6.


Review of the potential pharmacological role of erucic acid: a monounsaturated omega-9 fatty acid.

Kazmi I, Afzal M, Al-Abbasi F, Alghamdi S, Alghamdi A, Alzarea S Naunyn Schmiedebergs Arch Pharmacol. 2023; 397(6):3663-3674.

PMID: 38060041 DOI: 10.1007/s00210-023-02875-x.